Pharmaron Beijing company profile
Company profile
Pharmaron Beijing has 25,088 employees and is headquartered in Beijing, China.
Laboratory Services, the first of the five segments through which Pharmaron Beijing Co., Ltd. and its subsidiaries operate, provides chemistry and biological science services for small molecule drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates and cell and gene therapy products. The company also runs small molecule CDMO services, covering API process development and production, formulation and analytical development, alongside clinical research and macromolecular and cell and gene therapy services that span drug discovery through to production. Its customers are located in North America, Europe, Mainland China and across Asia.
In the fiscal year ended December 2025, the company reported revenue of 14.1 billion yuan, up 14.8% from the previous year, and net profit of 1.7 billion yuan. It had 25,088 employees and is headquartered in Beijing, where it was incorporated in 2004.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Headquarters
- Building 1, 100176, Beijing
- Employees
- 25,088
- Chief executive
- Boliang Lou
- Founded
- 2004
- Fiscal year
- January - December
- Listing
- 300759 · SZSE
- Currency
- CNY
- ISIN
- CNE100003JW4
- Website
- pharmaron.com
Pharmaron Beijing and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Pharmaron Beijing300759 | China | $10.59B | 25,088 | 14.0% | 39.3 |
| Sino Biopharmaceutical1177 | Hong Kong SAR China | $11.65B | 22,838 | 28.2% | 34.2 |
| ALTEOGEN196170 | South Korea | $9.05B | 181 | 47.2% | 97.1 |
| Haisco Pharmaceutical Group002653 | China | $8.97B | 5,597 | 21.1% | 44.1 |
| Genscript Biotech1548 | Hong Kong SAR China | $8.77B | 6,135 | 14.9% | — |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | Hong Kong SAR China | $12.15B | 2,300 | -0.2% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
